This article is available to subscribers. Subscribe now. Already have an account? Sign in

Original ArticleFree PreviewArchive

Psychotropic Drug Use and the Risk of Hip Fracture

List of authors.
  • Wayne A. Ray, Ph.D.,
  • Marie R. Griffin, M.D., M.P.H.,
  • William Schaffner, M.D.,
  • David K. Baugh, M.A.,
  • and L.Joseph Melton, III, M.D., M.P.H.

Abstract

To assess the risk of hip fracture associated with the use of four classes of psychotropic drugs, we performed a case-control study of 1021 patients with hip fractures and 5606 controls among elderly Medicaid enrollees. Persons treated with hypnotics–anxiolytics having short (≤24 hours) elimination half-lives had no increased risk of hip fracture. By contrast, a significantly increased risk was associated with current use of hypnotics–anxiolytics having long (>24 hours) elimination half-lives (odds ratio, 1.8; 95 percent confidence interval, 1.3 to 2.4), tricyclic antidepressants (odds ratio, 1.9; 95 percent confidence interval, 1.3 to 2.8), and antipsychotics (odds ratio, 2.0; 95 percent confidence interval, 1.6 to 2.6).

The risk increased in relation to the doses of drugs in these three classes. An analysis for possible confounding by dementia did not alter the results. Previous but noncurrent use of drugs in these classes conferred no increase in risk.

Although a cause- and-effect relation was not proved, these data support the hypothesis that the sedative and autonomic effects of psychotropic drugs increase the risk of falling and fractures in elderly persons. The results suggest the need for studies of this association in other populations and for evaluation of newer psychotropic drugs with fewer undesirable sedative and autonomic effects. (N Engl J Med 1987; 316:363–9.)

Funding and Disclosures

Supported in part by a grant (HS 05779) from the National Center for Health Services Research and Technology Assessment, a contract (500–81–0030) with the Health Care Financing Administration, and a Food and Drug Administration Cooperative Agreement (FD-U-000073–02). Dr. Ray is a Burroughs Wellcome Scholar in Pharmacoepidemiology.

We are indebted to Randy Fought, who performed the computer programming required for this study.

Author Affiliations

From the Division of Pharmacoepidemiology, Department of Preventive Medicine, Vanderbilt University School of Medicine, Nashville, the Office of Research and Demonstration, Health Care Financing Administration. Baltimore, and the Department of Medical Statistics and Epidemiology, Mayo Clinic and Mayo Foundation, Rochester, Minn. Address reprint requests to Dr. Ray at the Division of Pharmacoepidemiology, Department of Preventive Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232.

Print Subscriber? Activate your online access.